Clinical trial
Cholecalciferol in Treating Patients With Myelodysplastic Syndrome
NCT00068276 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00068276 |
|---|---|
| Title | Cholecalciferol in Treating Patients With Myelodysplastic Syndrome |
| Official title | Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms |
| Intervention type | Dietary Supplement |
| Interventions | cholecalciferol |
| Start date | Jul 1, 2003 |
| Primary completion | Jun 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Sep 11, 2003 |
| Last update posted | Aug 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: